Kathryn Weston Clerici

Kathryn Clerici is an associate in the firm’s Business Law Department. She joined Goodwin in 2019.

Ms. Clerici’s recent client representations include the following:

• BeiGene in its $2.08 billion registered direct offering
• Forma Therapeutics in connection with:
  • its $100 million Series D financing
  • its $319.3 million initial public offering
  • its $275.8 million follow-on offering
• Cullinan Oncology in its $287.4 million initial public offering
• Avadel Pharmaceuticals in connection with:
  • its $125 million follow-on offering
  • its $50 million at-the-market sales transaction
  • its $65 million private placement
• bluebird bio in its $575 million follow-on offering
• argenx in its $557 million follow-on offering
• The underwriters in IBEX’s $90.5 million initial public offering
• The underwriters in Pandion Therapeutics’ $135 million initial public offering
• resTORbio in its reverse merger with Adicet Bio

Ms. Clerici is a member of the Boston Bar Association.

While attending law school, Ms. Clerici worked as a corporate summer associate at Goodwin and a litigation summer associate at LibbyHoopes, P.C. in Boston. She was also an executive senior editor and a staff writer for the Boston College Law Review.